You are here : Home / All Sectors / Healthcare / Pharmaceuticals & Drugs / INDOCO REMEDIES

INDOCO REMEDIES
Intrinsic Value | Fundamental Analysis

Returns | 1W : 8.1% , 1M : -4.6%,1Y : 49.7%
www.indoco.com
BOM : 532612     NSE : INDOCO    
LT :  
    Long Term Analysis
Fundamentals : Average
Valuation : Bad [Stock is Expensive]
Debt : Average
Updated:
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Upward
Price Momentum : Downward
Pledged Shares : None or < 25%
Dec 08,2021
Price(EOD): Rs. 429.35
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
Affiliate Link.
Stock Market Investing Simplified- The best Video Course by Smart-Investing.in

Check out Industry Peers

Peers & Returns1W1M1Y
INDOCO REMEDIES 8.1% -4.6% 49.7%
SUN PHARMACEUTICAL INDUSTRIES -1.1% -5.3% 36.4%
DIVIS LABORATORIES -5.6% -10.5% 28.2%
DR REDDYS LABORATORIES -2.4% -4.1% -6.2%
CIPLA -2.6% -1.7% 17.3%
GLAND PHARMA -3.1% -3.4% 62.5%
PIRAMAL ENTERPRISES 4.5% -4.9% 81.4%
CADILA HEALTHCARE 0.4% -6.6% -0.4%
TORRENT PHARMACEUTICALS 5.5% 8.2% 14.4%


FUNDAMENTAL ANALYSIS OF INDOCO REMEDIES

 
Fundamentals Score
[ Q(TTM): Sep2021, Y: Mar2021
Q : Last Qtr data
Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
]
Show Me the Stocks with Fundamentals better than INDOCO REMEDIES Plus/Pro


VALUATION OF INDOCO REMEDIES

 
Valuation Score
[As on : Dec 08,2021 ]

Ratio Consolidated
P/E
P/B
P/S
42.51
P/E Calculated based on EPS of 10.1
[ Mar2021 - Consolidated Results ]

5.14
P/B Calculated based on Book Value of 83.45
[ Mar2021 - Consolidated Results ]

2.81
P/S Calculated based on Revenues of 1411.05 Cr
[ TTM - Consolidated Results ]

Show Me the Stocks with Valuation better than INDOCO REMEDIES Plus/Pro


FAIR VALUE OF INDOCO REMEDIES

 
Model Discount(-)/
Premium(+)
EV/EBIDTA
EV/Sales
Price/Sales
112%
62%
56%

SHARE PRICE MOMENTUM OF INDOCO REMEDIES

DEBT

Year Debt/Equity ratio
Standalone Consolidated
2021
2020
2019
Avg_3yrs
0.34
0.38
0.45
0.39
0.34
0.39
0.45
0.39
[Last Annual Data : Mar2021]

PLEDGED SHARES

Pledged Shares
0 %
As on : Sep2021

If less than 25%

Good
If between 25% and 50% Neutral
If greater than 50% Bad

QTRLY RESULTS

Consolidated Q-o-Q Y-o-Y
Revenue
Op Profit
Profit Before Tax
Profit After Tax
0.03%
-0.53%
5.97%
5.12%
17.86%
42.36%
76.59%
62.53%
QtrlyTrend
6
Latest Qtr: Sep2021

INDOCO REMEDIES related INDICES

BSE Indices1W1M1Y
S&P BSE 250 SMALLCAP 1.8% -2.1% 63.2%
S&P BSE SMALL CAP 1.6% -1.2% 66.7%
S&P BSE MIDSMALLCAP 1.5% -2% 57.2%
S&P BSE 400 MIDSMALLCAP 1.3% -2.5% 55.9%
S&P BSE ALLCAP 0.7% -2.8% 38.3%
S&P BSE 500 0.6% -3% 37.1%
S&P BSE HEALTHCARE -1.2% -0.5% 20.1%
NSE Indices1W1M1Y
NIFTY SMALLCAP250 2% -1% 67.9%
NIFTY MID SMALL400 1.5% -2.1% 56.5%
NIFTY500 MULTICAP 50:25:25 1% -2.4% NA
NIFTY 500 0.7% -2.9% 36.9%

You may also like the below Video Courses


FAQ [Frequently Asked Questions]


Is INDOCO REMEDIES good for long term investment?

As on 08-Dec-2021, the Fundamentals of INDOCO REMEDIES look Average and hence you may wait for the results to improve to invest for long term ! See Financial Performance of INDOCO REMEDIES . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!

Is INDOCO REMEDIES UnderValued or OverValued?

As on 08-Dec-2021, INDOCO REMEDIES is Over Valued based on the estimates of intrinsic value and hence may not be a good buying opportunity according to Share Valuation at this time!

What is the Intrinsic Value of INDOCO REMEDIES ?

As on 08-Dec-2021, the Intrinsic Value of INDOCO REMEDIES is Rs. 264.24 determined based on Median of the 3 historical models.
Fair Value [Median EV / EBIDTA Model] : Rs. 203.00
Fair Value [Median EV / Sales Model] : Rs. 264.24
Fair Value [Median Price / Sales Model] : Rs. 275.64
Median Fair Value of INDOCO REMEDIES : Rs. 264.24

Is INDOCO REMEDIES trading at a Premium or Discount?

As on 08-Dec-2021, INDOCO REMEDIES is trading at a Premium of 62% based on the estimates of Median Intrinsic Value!

What is the Financial Performance of Industry Peers of INDOCO REMEDIES ?

Check out Annual Financials of Industry Peers
Share Price & Financials of SUN PHARMACEUTICAL INDUSTRIES LTD | BOM: 524715 | NSE: SUNPHARMA
Share Price & Financials of DIVIS LABORATORIES LTD | BOM: 532488 | NSE: DIVISLAB
Share Price & Financials of DR REDDYS LABORATORIES LTD | BOM: 500124 | NSE: DRREDDY
Share Price & Financials of CIPLA LTD | BOM: 500087 | NSE: CIPLA
Share Price & Financials of GLAND PHARMA LTD | BOM: 543245 | NSE: GLAND
Check out Quarterly Results of Industry Peers
Quarterly Results of SUN PHARMACEUTICAL INDUSTRIES LTD
Quarterly Results of DIVIS LABORATORIES LTD
Quarterly Results of DR REDDYS LABORATORIES LTD
Quarterly Results of CIPLA LTD
Quarterly Results of GLAND PHARMA LTD

What are the Frequent Comparisons in this Industry?

Compare Analytics
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs DR REDDYS LABORATORIES LTD
CIPLA LTD vs GLAND PHARMA LTD vs PIRAMAL ENTERPRISES LTD
CADILA HEALTHCARE LTD vs TORRENT PHARMACEUTICALS LTD vs ALKEM LABORATORIES LTD
LUPIN LTD vs AUROBINDO PHARMA LTD vs BIOCON LTD
ABBOTT INDIA LTD vs LAURUS LABS LTD vs IPCA LABORATORIES LTD
Browse Market Cap of Industry Peers
Market Cap of SUN PHARMACEUTICAL INDUSTRIES LTD
Market Cap of DIVIS LABORATORIES LTD
Market Cap of DR REDDYS LABORATORIES LTD
Market Cap of CIPLA LTD
Market Cap of GLAND PHARMA LTD

Disclosure

SEBI Research Analyst
The Founder of this website, Mr. Rohit Katiyar is registered with SEBI as a Research Analyst [INH000007377].


All Stocks : A - Z

ALL   A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z